Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04380116 · ClinicalTrials.gov registry record · NA
Preliminary Effectiveness of Remotely Monitored Blood Alcohol Concentration Device as Treatment Modality
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 96
- Enrollment target
NCT04380116 is a NA study that has completed, run by Yale University. The registered enrollment target is 96 participants.
The verdict
NCT04380116, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 96 participants
- Enrollment target
Study Summary
State the scientific aim(s) of the study, or the hypotheses to be tested. The purpose of the current study is to evaluate the usage and acceptability of the Soberlink's blood alcohol concentration (BAC) unit in collaboration with Aware treatment to assess increased sobriety within patients suffering from alcohol use disorder (AUD). The specific AIMS will be: 1. To determine the effectiveness of Soberlink's ability to increase abstinence 2. To evaluate the impact of Soberlink's device on the participant based on their quality of health and sobriety. 3. To evaluate the extent to which need for higher levels of follow-up care and treatment is reduced for individuals who have had access to the Soberlink device.
Interventions
- DEVICE Soberlink
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2020-06-29 |
| Est. Completion | 2022-05-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04380116
The ClinicalTrials.gov registry entry for NCT04380116 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Soberlink is the first listed.
NCT04380116 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04380116 about?
NCT04380116 is a clinical study titled "Preliminary Effectiveness of Remotely Monitored Blood Alcohol Concentration Device as Treatment Modality". State the scientific aim(s) of the study, or the hypotheses to be tested. The purpose of the current study is to evaluate the usage and acceptability of the Soberlink's blood alcohol concentration (BAC) unit in collaboration with Aware treatment to assess increased sobriety within patients suffering...
What is the current status of trial NCT04380116?
This trial is currently completed. It is a NA study. The enrollment target is 96 participants. The study started on 2020-06-29. Estimated completion is 2022-05-01.
What interventions are being tested in trial NCT04380116?
The interventions under investigation include: Soberlink (DEVICE).
Who is sponsoring clinical trial NCT04380116?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.